Acute lymphoblastic leukemia

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

Retrieved on: 
Monday, April 8, 2024
FDA, Pharmaceutical, Health, Oncology, Acute lymphoblastic leukemia, Growth, Disease, Caregiver, New Drug Application, Patient, Nelarabine, NDA, Breast, Leukemia, Agency, Cancer, T-cell leukemia, Adenocarcinoma, Ovary, Food, Pharmaceutical industry

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.

Key Points: 
  • Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.
  • The Agency assigned a Prescription Drug User Fee Act (“PDUFA”) action date of November 30, 2024.
  • “With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of U.S. patients diagnosed with leukemia and other cancers who do not currently have the option of an oral liquid,” said Sharon Cunningham, Chief Executive Officer and Co-Founder of Shorla Oncology.
  • The company recently raised $35 million in Series B funding that has allowed Shorla to accelerate the growth of its oncology portfolio.

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

Retrieved on: 
Monday, April 8, 2024
NCI, Acute lymphoblastic leukemia, CLL, Immunotherapy, AML, TTC, Lung, Patient, ALL, NeXT, National Cancer Institute, Breast, Cancer, Pediatrics, Doctor of Philosophy, IND, GMP, Clinical trial, Investigational New Drug, Therapy, Immune system, Prognosis, Research institute, Cancer prevention, FDA, Lymphoma, CD127, Pharmaceutical industry

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127. CD127 is a receptor that is expressed in major subsets of multiple cancers including hematological cancers (ALL, AML, CLL, and lymphoma) and solid tumors (lung, breast, colorectal, H&N, esophageal cancers).

Key Points: 
  • Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127.
  • An addition to the $12M Product Development Award, Allterum received a $2.9M CPRIT seed award in 2020, which supported early-stage development work for the 4A10 antibody and laid the foundation for the current grant.
  • "We are pleased to provide Allterum with this TTC product development award to advance their promising anti-cancer drug into clinic," said Dr. Kenneth Smith, CPRIT's Chief Product Development Officer.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
Thursday, March 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

Global Cell Counting Market to Hit $15.72 Billion by 2029, Fueled by Advancements in Cell Biology and Therapy - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Research, Technology, University, Genetics, Artificial Intelligence, Education, Science, Nanotechnology, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Automation, Quality control, Interdisciplinarity, Acute lymphoblastic leukemia, Growth, Prevalence, Application, Novartis, Patient, Conditional sentence, Cell biology, Lung, Concha bullosa, Hospital, Artificial intelligence, National Cancer Institute, AI, Regenerative medicine, Duchenne muscular dystrophy, Therapy, DEB, Miniaturization, Sarepta Therapeutics, CGT, FDA, DMD, Tisagenlecleucel, PDUFA, Pharmaceutical industry

The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.

Key Points: 
  • The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.
  • Advancements in cell biology, biotechnology, and medical research are driving demand for precise cell counting, especially with the rise of personalized medicine and regenerative therapies.
  • PDUFA dates for therapies could translate into an order book boost for the cell counting players in the market, resulting in market growth.
  • The global cell counting market is consolidated, with top five players holding approximately 70% share of the market.

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: Pioneering New Drug Class with Versatile Therapeutic Potential - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Other Health, Health, Science, Pharmaceutical, Research, Multiple myeloma, Toxicity, Antigen, Haemophilia A, Cell, Autoimmunity, Patent, Carcinoma, Risk, Inflammation, Haemophilia, Malignancy, Monoclonal antibody, Neoplasm, Tissue, Patient, Tumor microenvironment, Antibody, Cancer, Bladder cancer, Leukemia, Diabetic retinopathy, Indication, Cytokine, Immune system, Therapy, Infection, Priority, Physician, Engineering, Escape Room, Acute lymphoblastic leukemia, Vaccine

The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types.
  • Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class.
  • Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:
    Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
    Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
    Clinical & Commercial Insight on Approved Bispecific Antibodies: 12 Antibodies
    Global Bispecific Antibodies Clinical Trials by Company, Indication & Phase: > 800 Antibodies
    FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points: 
  • In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
  • This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
  • This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
  • WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

Stop & Shop Fights Pediatric Cancer with Kick Off of ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Hospital, Acute lymphoblastic leukemia, MSK, Bruise, Doctor of Philosophy, MD, The Jimmy Fund, Physician, Malignancy, Friends, Cancer, Parent, Skin, Hope, Stop & Shop, EMPOWER, T-cell acute lymphoblastic leukemia, Dana–Farber Cancer Institute, Radiation, Mouth, Stop, Health, Kidney cancer, Adolescence, COVID-19, Wilms' tumor, Leukemia, Young adult, Patient, Family, Pediatrics, Child, Rhabdomyosarcoma, Estate (law), Research, Cheek

Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.

Key Points: 
  • Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.
  • 100% of proceeds will benefit the two hospitals to assist in their pioneering pediatric cancer treatment and care.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and non-malignant brain tumors.
  • “Stop & Shop’s dedication and generous support of pediatric cancer continues to help fund critical research and care,” said Scott Armstrong, MD, PhD, chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, MAIA, Gilead Sciences, Medicine, ASH, ASCO, SAB, FDA, Drug development, AbbVie, European Hematology Association, Mantle cell lymphoma, Pleasure, Kite Pharma, Hematology, EHA, University, Society, University of Bern, Patient, NK, Pharmacyclics, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

Immunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy Breakthroughs

Retrieved on: 
Wednesday, March 6, 2024
Bone marrow, Multimedia, Immunotherapy, SAB, FDA, Keio Medical Science Prize, University, Health, Dan, Patient, Knowledge, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

PISCATAWAY, N.J., March 6, 2024 /PRNewswire/ -- GenScript, a leading provider of life science research and application services, today proudly announced that Dr. Carl June, a distinguished figure in the field of immunotherapy, has joined the company's scientific advisory board (SAB).

Key Points: 
  • "Dr. June's vast experience in CAR T-cell therapy for cancer will provide invaluable insights for GenScript's initiatives," said Sherry Shao, Rotating Chief Executive Officer of GenScript.
  • "We are honored to welcome Dr. Carl June to the GenScript team and are eager to leverage his expertise as we develop more tools and solutions, particularly in the areas of cell and gene therapy."
  • "The SAB is composed of scientific leaders whose seminal research has significantly advanced the fields of genome editing and cell and gene therapy," said Ray Chen, Ph.D., President of the Life Science Group at GenScript.
  • With the addition of Dr. June, GenScript's SAB comprises leading experts across the spectrum of genome editing and cell and gene therapy.